OCT 30, 2019 9:14 PM PDT

How caloric restriction mimetics might prove helpful for cancer treatments

The benefits of fasting have been known to scientists and medical professionals for some time now, however, for many, the reality of fasting is not alluring. Perhaps that’s why a class of substances called caloric restriction mimetics (CMRs) has received so much attention in research investigations. Now, a new study published in EMBO Molecular Medicine details how one CMR, in particular, could be useful for treating age-related diseases like cancer and cardiovascular disease. The research team was led by Oliver Kepp and Guido Kroemer at the French Medical Research Council (INSERM).

CRMs are unique in their ability to mimic the anti-aging effects of fasting, without acting having to drastically change your lifestyle. These substances work because they induce cells into autophagy, a process that happens naturally during fasting in which cells stop the growth and begin to repurpose their own waste, thus clearing toxins and undesirable proteins. Some substances, such as spermidine and resveratrol have been shown to be correlated with human longevity and reduced cardiovascular and cancer-related mortality.

In order to find this new substance, the research team analyzed 200 compounds in the same class of CRMs as spermidine and resveratrol. While previous studies have proven the anti-aging effects of CRMs in species such as yeast, worms, and mice, the field is still emerging and lacks much research in humans. This study, comparable to past ones, has faced similar limitations.

CRMs may offer an alternative to a lifestyle change while still receiving the benefits of fasting. Photo: Pixabay

In their analysis, the team found that an agent called 3,4-dimethoxy chalcone (3,4-DC) was the most effective at inducing autophagy in a way that is not toxic to cells. They conducted these tests on rat and human cell cultures, and later on living mice. While they have still yet to test 3,4-DC in human trials, they found that the agent “protects against myocardial infarction and that it reduces the growth of tumors in the context of certain chemotherapeutic agents,” according to Science Daily.

“Altogether, our results suggest that 3,4‐DC is a novel CRM with a previously unrecognized mode of action,” write the authors. Furthermore, explains Science Daily, “The study is a proof of principle that the researchers' approach to testing substances in cell culture is a fast and efficient way to identify new CRM candidates with diverse modes of action.”

Sources: EMBO Molecular Medicine, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
MAR 31, 2021
Cancer
Understanding the risk of thrombosis for cancer patients
MAR 31, 2021
Understanding the risk of thrombosis for cancer patients
New research from the Comprehensive Cancer Center (CCC) of Medical University of Vienna and Vienna General Hospital sugg ...
APR 17, 2021
Drug Discovery & Development
Facebook AI May Speed up Cancer Drug Discovery
APR 17, 2021
Facebook AI May Speed up Cancer Drug Discovery
Facebook has claimed that its new artificial intelligence, known as 'Compositional Perturbation Autoencoder' (CP ...
APR 04, 2021
Drug Discovery & Development
Ion-Pump for Chemotherapy
APR 04, 2021
Ion-Pump for Chemotherapy
Patients of malignant brain tumors experience recurrences even after subsequent treatments. To address this issue, scien ...
APR 29, 2021
Cell & Molecular Biology
Cancer Cell Fate Influenced by Dietary Amino Acid
APR 29, 2021
Cancer Cell Fate Influenced by Dietary Amino Acid
This work could one day open up dietary therapeutic options for cancer.
MAY 06, 2021
Cancer
What accounts for the disparities in mortality rates from kidney cancer?
MAY 06, 2021
What accounts for the disparities in mortality rates from kidney cancer?
New research published in the journal Cancers attempts to address gaps in data regarding mortality risk from advanced-st ...
MAY 16, 2021
Cancer
Can you guess which drug is both antiviral and immunotherapeutic?
MAY 16, 2021
Can you guess which drug is both antiviral and immunotherapeutic?
Hepatitis B virus (HBV) is the most common cause of liver cancer in the world, resulting in approximately 880,000 deaths ...
Loading Comments...